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anOBJECTIVES The aim of this study was to examine the long-term prognosis in asymptomatic individuals with a cor-
onary artery calcium (CAC) score of 0 and its associated warranty period.
BACKGROUND Emerging evidence supports a CAC score of 0 as a favorable cardiovascular short-to intermediate-term
prognostic factor.
METHODS A total of 9,715 individuals undergoing CAC imaging were stratiﬁed by age, Framingham risk score (FRS), and
National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) categories and followed for a mean of
14.6 years (range 12.9 to 16.8 years). Cox regression, area under the receiver-operating characteristic curve, and net
reclassiﬁcation information were used to assess all-cause mortality, discrimination, and reclassiﬁcation of a CAC score of
0 compared with the FRS and NCEP ATP III, respectively. A warranty period was pre-deﬁned as <1% annual mortality
rate. Vascular age was estimated by linear regression.
RESULTS In 4,864 individuals with a baseline CAC score of 0 (mean age, 52.1  10.8 years; 57.9% male), 229 deaths
occurred. The warranty period of a CAC score of 0 was almost 15 years for individuals at low and intermediate risk with no
signiﬁcant differences regarding age and sex. A CAC score of 0 was associated with a vascular age of 1, 10, 20, and
30 years less than the chronological age of individuals between 50 and 59, 60 and 69, 70 and 79, and 80 years of age
and older, respectively. The CAC score was the strongest predictor of death (hazard ratio: 2.67, 95% conﬁdence interval:
2.29 to 3.11) that enabled discrimination and consistent reclassiﬁcation beyond the FRS (area under the receiver-
operating characteristic curve: 0.71 vs. 0.64, p < 0.001) and NCEP ATP III (area under the receiver-operating charac-
teristic curve: 0.72 vs. 0.64, p < 0.001).
CONCLUSIONS A CAC score of 0 confers a 15-year warranty period against mortality in individuals at low to inter-
mediate risk that is unaffected by age or sex. Furthermore, in individuals considered at high risk by clinical risk scores, a
CAC score of 0 confers better survival than in individuals at low to intermediate risk but with any CAC score.
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901AB BR E V I A T I O N S
AND ACRONYM S
CAC = coronary artery calcium
CAD = coronary artery disease
CI = conﬁdence interval
CT = computed tomography
EBCT = electron beam
computed tomography
FRS = Framingham risk score
HR = hazard ratio
NCEP ATP III = National
Cholesterol Education Program
Treatment Panel IIII n population-based studies, coronary artery cal-cium (CAC) scoring by computed tomography(CT) accurately stratiﬁes cardiovascular risk in
asymptomatic individuals (1–5). Notably, the pres-
ence (6,7), extent (8), and progression (9,10) of CAC
have been shown to be associated with major adverse
cardiovascular events (4,6–10) and death (3,4,10–15),
independent of conventional risk factors. Conversely,
a favorable prognosis has been observed in the
absence of CAC (16–18). The majority of these studies
have evaluated the beneﬁcial effect of a CAC score of
0 in cohorts with up to 5 years of follow-up, a time
point at which a generally low number of incident
adverse clinical events has occurred. However,SEE PAGE 910whether a CAC score of 0 confers long-term protec-
tion against poor survival incremental to and inde-
pendent of clinical risk scoring and its associated
“warranty period” remains to be elucidated. Further,
several recent studies highlighted the important
distinction between chronological age and “vascular
age,” the latter of which adjusts an individual’s risk
of mortality based on the level of CAC (19,20). To
date, the long-term impact of a CAC score of 0 for
the estimation of vascular age versus chronological
age is unknown. Thus, in the present study, we set
out to determine the long-term prognosis associated
with a CAC score of 0, comparing the prognosis of a
CAC score of 0 with the prognosis obtained by the
current clinical prediction models such as the Fra-
mingham risk score (FRS) and the National Choles-
terol Education Program Adult Treatment Panel III
(NCEP ATP III), quantifying the “warranty period”
for a CAC score of 0, and, last, examining the associ-
ation of a CAC score of 0 with chronological versus
vascular age.
METHODS
STUDY POPULATION. The study cohort comprised
9,715 consecutive asymptomatic individuals without
known coronary artery disease (CAD). All individuals
were referred by their physicians for CAD evaluationsupport from St. Jude Medical, American College of Radiology Imaging Netw
is supported by Leading Foreign Research Institute Recruitment Program t
funded by the Ministry of Science, ICT, & Future Planning (MSIP) grant 2012
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Manuscript received November 17, 2014; revised manuscript received Januaand underwent CAC imaging with electron
beam computed tomography (EBCT) at a
single site. All individuals provided informed
consent to undergo EBCT, and the study was
approved by the Human Investigations Com-
mittee at the Tennessee Heart and Vascular
Institute.
RISK FACTOR COLLECTION. All study par-
ticipants were queried for the following
baseline cardiovascular risk factors: 1) ciga-
rette smoking was considered to be present if
a subject was an active smoker at the time of
scanning; 2) dyslipidemia was considered to
be present for any individual reporting a history of
high total cholesterol, high low-density lipoprotein
cholesterol, low high-density lipoprotein cholesterol,
high triglycerides, or current use of lipid-lowering
therapy; 3) diabetes was deﬁned as baseline use of
antidiabetic medication or a history of elevated blood
glucose measurement of >126 mg/dl; 4) hypertension
was deﬁned as a self-reported history of high blood
pressure or the use of antihypertensive medication;
and 5) family history of premature CAD was deter-
mined by asking individuals whether any member of
their immediate family (i.e., parents or siblings) had
a history of fatal or nonfatal myocardial infarction
and/or coronary revascularization in a male relative
younger than 55 years of age or a female relative
younger than 65 years of age.
EBCT SCREENING PROTOCOL. Subjects underwent
EBCT on either a C-100 or C-150 Ultrafast CT scanner
(Imatron, South San Francisco, California). With a
tomographic slice thickness of 3 mm, a total of w40
sections were obtained beginning at the level of the
carina and proceeding caudally to the level of the dia-
phragm. Images were obtained with a 100-ms/slice
scanning time, with image acquisition electrocardio-
graphically triggered at 60% to 80% of the R-R interval.
A calciﬁed lesion was deﬁned as more than 3 contig-
uous pixels with a peak attenuation of at least 130
Hounsﬁeld units. Each lesion was then scored using
the method developed by Agatston et al. (21) (Agatston
units). The estimated radiation dose wasw1 mSv.
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TABLE 1 Clinical Cha
Risk Factor Coh
Age, yrs
Male
Hypertension
Dyslipidemia
Diabetes
Smoking
Family history of prem
Death
15-year survival
FRS*
Low (<10%)
Intermediate (10%–2
High (>20%)
NCEP ATP III†
Low (<10%)
Intermediate (10%–2
High (>20%) or DM
Values are mean  SD, %,
CAC ¼ coronary artery c
Risk Score; NCEP ATP III ¼
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902STUDY OUTCOME. The primary endpoint of this
study was death from all causes. Ascertainment of
mortality status was conducted by individuals blin-
ded to baseline historical data and EBCT results and
was veriﬁed using the U.S. Social Security Death In-
dex. The U.S. Social Security Death Index is a national
registry of all deaths that have occurred in the United
States, allowing for 100% mortality ascertainment
among study participants.
DEFINITION OF WARRANTY PERIOD. In accordance
with society guidelines, an annual mortality rate <1%
was used to deﬁne individuals as low risk (22). For the
purposes of this study, a warranty period was deﬁned
as the time that an individual remained in the low-
risk category; conversely, reported values of annual
mortality rate higher than 1% signiﬁed warranty
period cessation.
STATISTICAL METHODS. Categorical variables are
presented as count with proportion and continuous
variables as mean  SD. The Pearson chi-square test
was used for comparison of categorical variables.
Between-group comparisons of continuous variables
were computed using the independent-samples Stu-
dent t test or the Mann-Whitney U test, as app-
ropriate. Multivariable Cox proportional hazard
regression models reporting hazard ratios (HRs) with
95% conﬁdence intervals (95% CIs) were performed to
examine and compare the risk of death from all cau-
ses among individuals. The latter model adjusted forracteristics of the Study Sample
ort
Overall
(N ¼ 9,715)
CAC ¼ 0
(n ¼ 4,864)
CAC >0
(n ¼ 4,851) p Value
53.4  10.5 52.1  10.8 54.6  10.0 <0.001
59.3 57.9 60.8 0.003
43.4 36.8 50.1 <0.001
62.6 57.8 67.3 <0.001
8.3 5.7 11.0 <0.001
39.3 33.6 45.0 <0.001
ature CAD 68.7 69.7 67.7 0.03
936 (9.6) 229 (4.7) 707 (14.6) <0.001
89.6 95.1 83.7 <0.001
<0.001
40.7 50.0 31.4
0%) 41.3 37.3 45.3
18.0 12.7 23.3
<0.001
53.4 62.9 43.8
0%) 27.7 23.7 31.8
18.9 13.4 24.4
or n (%). *Wilson et al. (23). †Shaw et al. (3).
alcium; CAD ¼ coronary artery disease; DM ¼ diabetes mellitus; FRS ¼ Framingham
National Cholesterol Education Program Adult Treatment Panel III.age, sex, cigarette smoking, and cardiovascular mor-
bidities including diabetes, hypertension, dyslipide-
mia, and family history of premature CAD.
The relationship between a CAC score of 0 and
mortality was determined as a function of varying
cardiovascular risk as determined by widely used
clinical risk scores. Cox regression models stratiﬁed
individuals according to pre-deﬁned categories as
quantiﬁed by low (<10%), intermediate (10% to 20%),
and high (>20%) risk using 10-year FRS and NCEP
ATP III score (3,23).
Linear regression models were used to estimate the
vascular age using patients’ chronological age as the
dependent variable and the CAC score as the inde-
pendent variable (19). Group differences between
vascular age and chronological age were plotted.
Additionally, for each corresponding category of age,
annual mortality rates were calculated. The discrimi-
natory power of the CAC score over FRS and NCEP ATP
III was evaluated using the area under the receiver-
operating characteristic curve (24) and compared us-
ing the DeLong method (25). Reclassiﬁcation was
determined using category-free net reclassiﬁcation
improvement indexes (26). Statistical analyses were
performed using STATA version 12.0 (StataCorp
LP, College Station, Texas) and SAS version 9.3
(SAS Institute Inc., Cary, North Carolina). A 2-tailed
p value <0.05 was considered statistically signiﬁcant.
RESULTS
STUDY POPULATION. Of 9,715 individuals (mean age
53.4  10.5 years, 59.3% male) undergoing CAC
screening, 4,864 (mean age, 52.1  10.8 years; 57.9%
male) had a CAC score of 0. At a mean follow-up of
14.6 years (range 12.9 to 16.8 years), there were 936
(9.6%) deaths in the study population. Of the deaths,
229 (4.7%) and 707 (14.6%) occurred in individuals
with CAC scores of 0 and >0, respectively. De-
mographic characteristics of the study sample are
summarized in Table 1. Overall, hypertension, dysli-
pidemia, smoking status, diabetes, family history of
premature CAD were more prevalent and FRS and
NCEP ATP III were higher among individuals with a
CAC score >0 versus a CAC score of 0. The survival
rate was higher for those with a CAC score of 0 (95.1%
vs. 83.7%, p < 0.001).
CAC AND LONG-TERM PROGNOSIS. On multivari-
able analyses, a CAC score >0 was the strongest pre-
dictor of death in the overall population beyond
individual cardiovascular risk factors, FRS, and NCEP
ATP III and was associated with a nearly 3-fold risk of
death (HR: 2.67, 95% CI: 2.29 to 3.11) (Table 2). The
presence of diabetes (HR: 2.53, 95% CI: 1.74 to 3.69),
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903active smoking (HR: 1.95, 95% CI: 1.50 to 2.53), and
hypertension (HR: 1.58, 95% CI: 1.21 to 2.06) were
associated with an increased risk of mortality among
individuals with a CAC score of 0. In the presence of
any CAC, the risk increased proportionally with the
severity in the CAC score but independently of the
FRS and the risk model provided by the NCEP ATP III
(Table 3). Men and women showed similar survival
and mortality risk in either the presence or absence of
CAC (Online Figures 1A and 1B).
WARRANTY PERIOD OF A CAC SCORE OF 0. Figure 1
describes the 15-year cumulative mortality rate in all
study individuals and those considered at low risk by
the FRS, NCEP ATP III, absence of CAD risk factors, and
CAC score of 0; individuals with a CAC score of 0 had
the lowest rates of mortality. Independent of FRS
(Figure 2A) or NCEP ATP III (Figure 2B), a CAC score of
0was associatedwith a favorable prognosis. Risk of all-
cause mortality was higher in individuals with a CAC
score>0 and low cardiovascular risk (FRS, HR: 3.3; 95%
CI: 2.49 to 4.32; NCEP ATP III, HR: 3.09; 95% CI: 2.45 to
3.90) compared with those with a CAC score of 0 and
high cardiovascular risk (FRS, HR: 2.8; 95% CI: 2.05 to
3.92; NCEP ATP III, HR: 2.94; 95% CI: 2.15 to 4.01).
Figure 3 shows the annual mortality rates for in-
dividuals with CAC scores of 0 and >0. A CAC score of
0 was associated with a warranty period longer than
15 years, with the observed rate of mortality
remaining <1% during the entire follow-up. Mortality
rates in individuals with a CAC score of 0 were
nonlinear in nature, with a lower event rate (0.3% 
0.08% events/year) during the initial 12 years that
accelerated during the 13th (0.4% events/year)
and 14th (0.58% events/year) years. Figure 4
depicts the warranty period of a CAC score of 0 in
select subgroups. A CAC score of 0 was associated
with a warranty period of 15 years for individuals
younger than 60 years of age, with no apparent
disparity between sexes. The observed duration of
the warranty period of a CAC score of 0 was slightly
shorter for those 60 years of age and older and ceased
after 14 years of follow-up. Despite a CAC score of 0,
individuals considered at high cardiovascular risk by
clinical risk experienced a signiﬁcantly shorter war-
ranty period (5 to 6 years) than individuals at low to
intermediate risk. However, the warranty period for
high-risk categories with a CAC score of 0 was even
longer than for individuals at low to intermediate risk
with a CAC score >0.
VASCULAR AGE IN INDIVIDUALS WITH A CAC SCORE
OF 0. A CAC score of 0 was associated with a lower
vascular versus chronological age, a ﬁnding more
pronounced for individuals of increasing age and for
TABLE 3 Hazard Ratio Analysis of 15-Year All-Cause Mortality in Asymptomatic Individuals According to the CAC Score
CAC Score
Overall
(N ¼ 9,715)
Univariable
Multivariable
Adjusted for FRS Adjusted for NCEP ATP III
0 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)
1–99 2.21 (1.86–2.64), p < 0.001 2.08 (1.74–2.48), p < 0.001 2.03 (1.70–2.42), p < 0.001
100–399 3.85 (3.19–4.66), p < 0.001 3.42 (2.83–4.14), p < 0.001 3.32 (2.74–4.02), p < 0.001
400–999 5.98 (4.84–7.39), p < 0.001 4.93 (3.98–6.12), p < 0.001 4.81 (3.87–5.97), p < 0.001
$1,000 8.66 (6.79–11.05), p < 0.001 6.79 (5.29–8.72), p < 0.001 6.99 (5.46–8.95), p < 0.001
Values are hazard ratio (95% conﬁdence interval).
Abbreviations as in Table 1.
FIGURE 1 The 15-Y
Overall (N = 9,715
No CV risk factors
Cu
m
ul
at
iv
e 
M
or
ta
lit
y 
Ra
te
 (%
)
1 2
12.0
10.0
8.0
6.0
4.0
2.0
0.0
The 15-year cumulati
and individuals consi
the absence of any c
0 (green line). CAC
risk score; NCEP ATP
Panel III.
Valenti et al. J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 8 , N O . 8 , 2 0 1 5
Asymptomatic Individuals Without CAC A U G U S T 2 0 1 5 : 9 0 0 – 9
904men versus women (Figure 5A). As an example, the
vascular age afforded by a CAC score of 0 for a man 80
years of age and older was equivalent to the chrono-
logical age of a 50-year-old man in the general pop-
ulation. The annual mortality rate observed for
patients with a CAC score of 0 was lower than the
equivalent category of chronological age in the gen-
eral population (Figure 5B).
INCREMENTAL PREDICTIVE VALUE OF CAC FOR
INDIVIDUALS WITH A CAC SCORE >0. Compared
with the base models of FRS or NCEP ATP III alone,
discrimination improved signiﬁcantly (area under the
receiver-operating characteristic curve, 0.71 vs. 0.64ear Cumulative Mortality Rate for the Study Period
) FRS < 10% (N = 3,954)
 (N = 545) CAC = 0 (N = 4,864)
Year
3 4 5 6 7 8 9 10 11 12 13 14 15
NCEP ATP III < 10% (N = 5,185)
ve mortality rate according to the overall study population (pink line)
dered low risk by FRS (light blue line), NCEP ATP III (dark blue line),
oronary artery disease risk factor (yellow line), and CAC score of
¼ coronary artery calcium; CV ¼ cardiovascular; FRS ¼ Framingham
III ¼ National Cholesterol Education Program Adult Treatmentand 0.72 vs. 0.64 for FRS and NCEP ATP III, respec-
tively; p < 0.001 for both) when the CAC score was
added to the FRS or NCEP ATP III. The addition of the
CAC score to the FRS or NCEP ATP III also resulted in
signiﬁcant reclassiﬁcation of events and nonevents
among individuals (both p < 0.001). Irrespective of
risk prediction category, CAC score improved risk
classiﬁcation for those at risk versus not at risk of
incident mortality (p < 0.001) (Table 4).
DISCUSSION
In the present study, we extensively examined the
long-term prognostic utility of CAC imaging in a large
cohort of asymptomatic individuals with 15 years of
follow-up. We observed the presence of CAC to be a
strong predictor of incident mortality, even when
considering robust clinical risk scores by FRS or NCEP
ATP III methods. Importantly, we identiﬁed a very
low risk state that lasted for the duration of follow-
up. The low risk associated with a CAC score of
0 persisted for more than 15 years for individuals
younger than 60 years of age and for 14 years for in-
dividuals 60 years of age and older, with no apparent
disparity among sexes. Importantly, the warranty
period conferred by a CAC score of 0 was similar for
individuals at low- or intermediate-clinical risk by the
FRS and NCEP ATP III. Individuals considered at high
clinical risk but with a CAC score of 0 had a longer
warranty period than those at low- or intermediate-
clinical risk with any CAC score. Conversely, the
presence and severity of CAC were independently
associated with increased mortality risk by the FRS
and the NCEP ATP III. Finally, a CAC score of 0 was
associated with a vascular age that was w30 years
lower than chronological age for older individuals
and was associated with a signiﬁcantly lower annual
mortality rate than the equivalent chronological age
category. Taken together, these ﬁndings indicate the
robustness of a CAC score of 0 to identify individuals
FIGURE 2 Hazard Ratios for Risk of All-Cause Mortality
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FIGURE 3 Annual Mortality Rate During the Study Period
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FIGURE 4 Observed Warranty Period for the Absence of CAC Compared With the Presence of CAC
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906disposed to a particularly propitious outcome and
may be useful as an adjunctive measure for everyday
clinical risk assessment.
The present ﬁndings support and expand the
extant literature (16–18) on studies that investigated
the incremental utility of CAC imaging for the eval-
uation of asymptomatic individuals at risk of cardio-
vascular disease. The high prevalence of a CAC score
of 0 in individuals classiﬁed as intermediate to high
risk based by clinical risk scores suggests that such
scores are highly imperfect in identifying persons at
increased risk of mortality (27,28). To this end, the
present study detected a signiﬁcantly higher risk of
mortality for individuals with a CAC score >0 who
were considered at low risk by clinical score with
respect to those with a CAC score of 0 who were
considered at intermediate or high risk. Yet, although
robust in risk prediction, a CAC score of 0 was
signiﬁcantly less effective at conferring a long-term
warranty for individuals considered high risk by the
FRS and NCEP ATP III. Thus, although currentguidelines support the use of CAC imaging in
asymptomatic individuals at intermediate cardiovas-
cular risk (29), the present study suggests a long-term
incremental value of a CAC score >0 for individuals
initially considered to be at low risk but who are
subsequently reclassiﬁed as at high cardiovascular
risk based on CAC testing. Whether there is a clinical
beneﬁt of identiﬁcation of a shorter warranty period
of 5 to 6 years for individuals considered to be at high
risk by FRS or NCEP ATP III requires further exami-
nation in health outcomes studies.
In this study, the beneﬁcial prognosis of a CAC score
of 0 is further supported by evidence of a vascular age
reduction compared with chronological age, with an
associated improvement in prognosis. Although it is
generally accepted that the prevalence of coronary
plaque burden and mortality rate increase with
advancing age, the presence of a CAC score of 0 may be
effective as an index of “vascular youth” (19,20).
These study ﬁndings validate the concept of “vascular
youth,” as determined by a CAC score of 0, in which
FIGURE 5 Differences Between Chronological and Vascular Age
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907individuals older than 50 years of age may be reas-
sured that their coronary vasculature is “younger”
than that of their peers and that this auspicious ﬁnding
confers a good long-term prognosis.TABLE 4 NRI With the Addition of CAC Scoring to a Model Including
NRI 95% CI p Value
Overall cohort (N ¼ 9,715)
FRS þ CAC 0.58966 0.5251–0.6542 <0.0001
NCEP ATP III þ CAC 0.57966 0.5149–0.6444 <0.0001
Low cardiovascular risk
FRS þ CAC 0.52561 0.3961–0.6551 <0.0001
NCEP ATP III þ CAC 0.49967 0.3878–0.6116 <0.0001
Intermediate cardiovascular risk
FRS þ CAC 0.46417 0.3611–0.5672 <0.0001
NCEP ATP III þ CAC 0.51544 0.3955–0.6354 <0.0001
High cardiovascular risk
FRS þ CAC 0.58347 0.4709–0.6961 <0.0001
NCEP ATP III þ CAC 0.55956 0.4494–0.6698 <0.0001
CI ¼ conﬁdence interval; NRI ¼ net reclassiﬁcation improvement; other abbreviations asThese study ﬁndings are of high clinical impor-
tance. Given the 15-year warranty of a CAC score of
0 for individuals at low to intermediate clinical risk
irrespective of sex and age—a period only slightlythe FRS or NCEP ATP III Score
% of Events
Correctly Reclassiﬁed
Event
p Value
% of Nonevents
Correctly Reclassiﬁed
Nonevent
p value
29 <0.0001 30 <0.0001
28 <0.0001 30 <0.0001
12 0.07 41 <0.0001
13 0.02 37 <0.0001
23 <0.0001 23 <0.0001
28 <0.0001 23 <0.0001
40 <0.0001 18 <0.0001
37 <0.0001 19 <0.0001
in Table 1.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Traditionally, CAD has been assessed in terms of
measures of stenosis severity. Characterization of
atherosclerotic plaque characteristics, in addition to
stenosis severity, may improve the diagnosis and
prognostic risk assessment of patients with CAD.
Features suggesting high-risk as seen with computed
tomography include atherosclerotic plaque and
coronary artery calciﬁcation volume and density and
others, such as low attenuation plaque, positive
remodeling, and spotty calciﬁcation. Conversely, the
absence of CAC is protective against coronary events
during long-term follow-up.
TRANSLATIONAL OUTLOOK: Additional clinical
studies are required to determine the optimal
methods for reporting CAD measures of stenosis or
atherosclerosis, as well as to determine their prog-
nostic implications and optimal approaches to
therapy.
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908attenuated for patients 60 years of age and older—the
use of CAC may be instrumental for avoiding unnec-
essary testing, even in individuals generally consid-
ered at higher risk of unexpected adverse clinical
events. Although some may speculate that the prog-
nostic security of a CAC score of 0 may offer an op-
portunity to attenuate medical therapies, our study
ﬁndings apply only to coronary rather than cardio-
vascular assessment in other vascular beds such as
the carotid circulation. Thus, the present results
should not be interpreted as supporting a practice of
therapy diminution or cessation as this matter is
beyond the scope of our investigation. Future large-
scale studies examining this concept should ﬁrst be
performed.
STUDY LIMITATIONS. This study is not without limi-
tations. Despite the large study sample size, long-term
follow-up, and prospective evaluation of study in-
dividuals, the single-center design of the present
study may have introduced unobserved biases related
to selection. In this regard, future population-based
studies with long-term follow-up will be important
to help conﬁrm the present study ﬁndings. Further,
CAC imaging was performed only once for the present
study, and the rates of CAC progression were not
accounted for in the determination of the warranty
period of a CAC score of 0. It remains conceivable that
individuals who experience accelerated or retarded
CAC progression may have different warranty periods,
and future studies should be performed to examine
this. Also, the long-term mitigating effects of medical
therapy and lifestyle modiﬁcation and how they might
inﬂuence the relationship between CAC and mortality
cannot be accounted for in this investigation. Hence,
future studies that use time-varying clinical measures
in patients with known CAC values are now needed.
Finally, we used all-cause mortality as the primary
endpoint for this study, and, thus, our analysis is un-
able to offer information regarding the impact of CAC
speciﬁcally on cardiovascular morbidity and mortal-
ity, such as that used for the 2013 American College of
Cardiology/American Heart Association guidelines
(30). However, the use of mortality disentangles the
study from ascertainment or misclassiﬁcation bias and
represents the most difﬁcult endpoint to be evaluated
in population studies. Indeed, the lack atheroscleroticcardiovascular disease–speciﬁc mortality in our study
may have only contributed to an underestimation of
the real impact of CAC on cardiovascular risk (31).
CONCLUSIONS
A CAC score of 0 confers a 15-year warranty period
against mortality that is unaffected by age or sex,
with a signiﬁcant reduction in vascular rather than
chronological age. These ﬁndings are consistent in
individuals at low and intermediate risk. In in-
dividuals considered at high risk by clinical risk
scores, the presence of a CAC score of 0 confers a
longer warranty period compared with individuals at
low or intermediate risk in the presence of any CAC.
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